Tibet Weixinkang Medicine Co., Ltd.

SHSE:603676 Voorraadrapport

Marktkapitalisatie: CN¥4.4b

Tibet Weixinkang Medicine Inkomsten in het verleden

Verleden criteriumcontroles 3/6

Tibet Weixinkang Medicine has been growing earnings at an average annual rate of 35.3%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 14.9% per year. Tibet Weixinkang Medicine's return on equity is 16.7%, and it has net margins of 19.7%.

Belangrijke informatie

35.3%

Groei van de winst

34.8%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie10.9%
Inkomstengroei14.9%
Rendement op eigen vermogen16.7%
Nettomarge19.7%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Concerns Surrounding Tibet Weixinkang Medicine's (SHSE:603676) Performance

Sep 03
Concerns Surrounding Tibet Weixinkang Medicine's (SHSE:603676) Performance

Recent updates

With EPS Growth And More, Tibet Weixinkang Medicine (SHSE:603676) Makes An Interesting Case

Oct 01
With EPS Growth And More, Tibet Weixinkang Medicine (SHSE:603676) Makes An Interesting Case

Concerns Surrounding Tibet Weixinkang Medicine's (SHSE:603676) Performance

Sep 03
Concerns Surrounding Tibet Weixinkang Medicine's (SHSE:603676) Performance

Take Care Before Diving Into The Deep End On Tibet Weixinkang Medicine Co., Ltd. (SHSE:603676)

Apr 16
Take Care Before Diving Into The Deep End On Tibet Weixinkang Medicine Co., Ltd. (SHSE:603676)

Opbrengsten en kosten

Hoe Tibet Weixinkang Medicine geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

SHSE:603676 Opbrengsten, kosten en inkomsten (CNY Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 241,256247368119
30 Jun 241,206243366121
31 Mar 241,290249391122
31 Dec 231,323214402113
30 Sep 231,393236433102
30 Jun 231,48020847790
31 Mar 231,43419847078
31 Dec 221,39917748472
30 Sep 221,34916546157
30 Jun 221,20214642749
31 Mar 221,14111641844
31 Dec 211,0349638838
30 Sep 211,0019635433
30 Jun 219348232827
31 Mar 217946629422
31 Dec 207165826321
30 Sep 206595625314
30 Jun 206754825820
31 Mar 207164626323
31 Dec 197415627526
30 Sep 198175330326
30 Jun 197935431225
31 Mar 197476028724
31 Dec 187467327021
30 Sep 186168922621
30 Jun 185329315331
31 Mar 1849711515727
31 Dec 1742010213823
30 Sep 1742111312218
30 Jun 174021151440
31 Mar 174251141730
31 Dec 164261151480
31 Dec 154401131530
31 Dec 143911071350

Kwaliteitswinsten: 603676 has a large one-off gain of CN¥57.1M impacting its last 12 months of financial results to 30th September, 2024.

Groeiende winstmarge: 603676's current net profit margins (19.7%) are higher than last year (17%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 603676's earnings have grown significantly by 35.3% per year over the past 5 years.

Versnelling van de groei: 603676's earnings growth over the past year (4.6%) is below its 5-year average (35.3% per year).

Winst versus industrie: 603676 earnings growth over the past year (4.6%) exceeded the Pharmaceuticals industry -1.2%.

Rendement op eigen vermogen

Hoge ROE: 603676's Return on Equity (16.7%) is considered low.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y